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Abstract 
Rationale  Major depressive disorder is a leading cause of suicide and disability.  Despite this, 
current antidepressants provide insufficient efficacy in more than 60% of patients.  Most current 
antidepressants are pre-synaptic reuptake inhibitors; postsynaptic signal regulation has not 
received as much attention as potential treatment targets. 
Objectives  We examined the effects of disruption of the postsynaptic cyclic nucleotide 
hydrolyzing enzyme, phosphodiesterase (PDE) 1b, on depressive-like behavior and the effects 
on PDE1B protein in wild-type (WT) mice following stress. 
Methods  Littermate knockout (KO) and WT mice were in locomotor activity, tail suspension 
(TST), and forced swim tests (FST).  FST was also used to compare the effects of two 
antidepressants, fluoxetine and bupropion, in KO versus WT mice.  mRNA expression changes 
were also determined.  WT mice underwent acute or chronic stress and markers of stress and 
PDE1B expression examined. 
Results  Pde1b KO mice exhibited decreased TST and FST immobility.  When treated with 
antidepressants, both WT and KO mice showed decreased FST immobility and the effect 
additive in KO mice.  Mice lacking Pde1b had increased striatal Pde10a mRNA expression.  In 
WT mice, acute and chronic stress upregulated PDE1B expression while PDE10A expression 
was downregulated after chronic but not acute stress.  
Conclusions  PDE1B is a potential therapeutic target for depression treatment because of the 
antidepressant-like phenotype seen in Pde1b KO mice. 
Key words: Phosphodiesterase; PDE1B; Pde1b knockout mice; stress resistance; forced swim 
test; Pde brain gene expression 
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Introduction 
Depression is a leading cause of disability, with a lifetime prevalence of 16% (Kennedy 
2013).  The Centers for Disease Control and Prevention report that two-thirds of suicides are 
depression-related (Cassano and Fava 2002).  In the United States, 83.1 billion dollars is spent 
annually treating depression, yet current treatments are often not effective (Greenberg et al. 
2003). 
Most antidepressants target presynaptic neurotransmitter reuptake transporters; 
postsynaptic targets have received less attention.  A potential postsynaptic site for modulating 
neuronal activity is through influencing the duration of action of second messengers (cyclic 
adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP)).  Increased 
levels of cGMP have been associated with antidepressant efficacy by increasing neuronal 
activity (Reierson et al. 2011).  This may contribute to secondary effects, such as promoting 
progenitor cell proliferation in the subventricular and subgranular zones (Gómez-Pinedo et al. 
2010; Reierson et al. 2011). 
Phosphodiesterases (PDEs) hydrolyze the phosphodiester bond of cAMP and/or cGMP.  
There are 11 PDE families composed of 21 isoforms each with a different specificity for cAMP, 
cGMP, or both.  Most PDEs have distinct tissue distributions (Maurice et al. 2014).  The rate of 
hydrolysis determines the duration of cyclic nucleotide signaling on downstream effectors such 
as protein kinase A (PKA), protein kinase G, exchange protein activated by cAMP, and cyclic 
nucleotide gated channels (Conti and Beavo 2007). 
Human and animal studies have linked other PDEs (e.g., PDE4) to depression 
(O'Donnell and Zhang 2004).  Patients with major depressive disorder have decreased positron 
emission tomography binding of 11C-(R)-rolipram, a PDE4 inhibitor, (Fujita et al. 2012).  Chronic 
exposure to antidepressants, including rolipram, increase levels of brain-derived neurotropic 
factor and neurogenesis through the activation of the PKA and phosphorylated cAMP-response 
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binding protein (Duman et al. 1999).  Rodents treated with etazolate, another PDE4 inhibitor, 
exhibit antidepressive-like changes on tests of locomotor activity, tail suspension test (TST), and 
forced swim test (FST); it is also effective at blocking the induction of depressive-like behaviors 
caused by chronic mild stress (CMS) (Jindal et al. 2013; Jindal et al. 2012).  RNA interference 
or knockout (KO) of Pde4d increases cAMP signaling and decreases immobility in the TST and 
the FST in mice and in the FST in rats (Schaefer et al. 2012; Wang et al. 2013; Zhang et al. 
2002).  In humans, PDE4 inhibitors have antidepressant effects, however they also cause 
unacceptable gastrointestinal side-effects (Hansen and Zhang 2015). 
An alternate PDE target for depression is PDE1.  Vinpocetine, a PDE1 inhibitor, 
produced enhancement of long-term potentiation (LTP) and increased dendritic spine density in 
rats, suggesting that PDE1 inhibitors have neurotrophic effects (Filgueiras et al. 2010).  There 
are three PDE1 subtypes: A, B, and C.  PDE1A is in brain, heart, lung, and testis and is involved 
in regulating vascular smooth muscle (Kim et al. 2001).  PDE1C is found in brain, heart, and 
testis and promotes arterial smooth muscle cell proliferation and down-regulation of glucose-
induced insulin secretion (Han et al. 1999; Rybalkin et al. 2002).  PDE1 is a dual substrate for 
cAMP and cGMP and is found in areas rich in dopamine (DA) (Essayan 2001), including the 
caudate-putamen, nucleus accumbens, dentate gyrus, and substania nigra, areas linked to 
mood and other functions (Lakics et al. 2010; Polli and Kincaid 1994).  The described 
neurotrophic effects of PDE1 inhibitors and the localization of PDE1B suggests it might be 
promising in relation to depression.  We created a constitutive Pde1b KO mouse (Reed 2000).  
These mice exhibit minor increases in locomotor activity (Reed 2000), differential responses to 
stimulants, but in one report, no change in FST behavior (Siuciak et al. 2007).  However, in the 
latter study the mice were on a mixed background, whereas our mice were back-crossed 10 
generations.  Previously, we crossed Pde1b KO mice with Darpp32 KO mice [dopamine and 
cyclic-adenosine 5’-phosphate (cAMP)-regulated phosphoprotein, Mr 32 kDa that plays a role in 
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dopaminergic and serotonergic pathways].  Pde1b-Darpp32 double KO (dKO) mice exhibited 
increased DA turnover in striatum (Ehrman et al. 2006) compared with single KO and WT mice 
(Ehrman et al. 2006; Fienberg et al. 1998; Reed et al. 2002; Svenningsson et al. 2000; 
Svenningsson et al. 2004; Svenningsson et al. 2003; Svenningsson et al. 2002).  These data 
suggest that PDE1B may be involved in DA signaling, and DA has been implicated in 
depression (Chaudhury et al., 2013).  Accordingly, we hypothesized that Pde1b disruption 
would result in a stress/depressive-resistant phenotype. 
 
Methods 
Animals and Husbandry 
Mice used for experiment 1 were congenic C57BL/6N KO mice bred in house from 
heterozygous (Pde1b+/- x Pde1b+/-) parents to obtain litters containing WT, KO, and 
heterozygous littermates (Reed et al. 2002).  Mice were tested as adults (postnatal day (P) 60 
or later) with not more than one mouse per genotype per litter used where possible to control for 
litter effects.  Offspring were housed 2-4 per cage after weaning.  All mice were housed in 
polysulfone cages in a pathogen free vivarium using Modular Animal Caging System 
(Alternative Design, Siloam Spring, AR) with HEPA filtered air (Alternative Design, Siloam 
Spring, AR) at 30 air changes/h.  Water was provided ad libitum using an automated reverse-
osmosis filtering system (SE Lab Group, Napa, CA).  Cages had ad libitum food, corncob 
bedding, and cotton nest material.  Mice were maintained on a 14 h light-10 h dark cycle (lights 
on at 600 h) that is standard in our institution’s vivarium.  Protocols were approved by the 
Institutional Animal Care and Use Committee.  The vivarium is accredited by AAALAC 
International.  Wild-type C57BL/6J male mice used in experiment 2 were purchased from 
Jackson Laboratories, randomly assigned to treatment groups, given one week to acclimate 
before experiments, and housed four per cage.  All behavioral testing was done blind to the 
Page 5 of 38 Psychopharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6 
 
genotype, and all behavioral testing was done in the Animal Behavioral Core at Cincinnati 
Children’s with the exception of those mice tested at Mount St. Joseph University (see below).  
Sample sizes for each experiment are given in figure legends and Table 1. 
Experiment 1: KO phenotype and mRNA Pde isoform expression 
Reverse Transcription-qPCR 
 
RNA was isolated from the striatum and cerebellum of 4 KO and 5 WT mice using the 
RNeasy kit (Qiagen) according to manufacturer’s instructions.  The striatum was chosen 
because it is the region of highest Pde1b expression; the cerebellum was chosen as a negative 
control region.  The RNA was treated with TURBO DNase (Ambion), quantified by Nanodrop 
(Thermo Scientific), and integrity measured on an Agilent 2100 Bioanalyzer using an RNA Nano 
6000 Labchip (Agilent).  The RNA integrity number ranged from 8.3 to 9.5.  Reverse 
transcription (RT) reactions were performed using 1 x reaction buffer, 2.5 mM MgCl2, 1 µg of 
RNA template, 2.5 µM random hexamers, 0.25 mM of each dNTP, 40 U RNase inhibitor, 150 U 
MMLV-RT (Applied Biosystems) in a final volume of 100 µL.  Reactions lacking the RT enzyme 
(RT-) were used as negative controls.  Reactions were carried out in a PCR machine using the 
following program: 10 min at 25 oC, 60 min at 37 oC, and 5 min at 75 oC.  Quantitative PCR 
(qPCR) contained 80 ng of cDNA, 300 nM of each primer (forward and reverse), and 1x SYBR 
Green Master Mix (Qiagen) in a 40 µL volume.  Four 5 µL aliquots of the mix were placed in a 
384-well plate and the qPCR was performed on an ABI Prism 7900HT (Applied Biosystems) 
using the following cycling conditions: 50 oC for 2 min, 95 oC for 10 min, and 40 cycles at 95 oC 
for 15 s and 60 oC for 1 min.  Primers were synthesized by Eurofins Genomics (Ebersberg, 
Germany) and selected for this study based on primer efficiency, empirically determined to be 
95 - 100%.  Mouse primer sequences are listed in Table 1.  Negative controls included qPCR 
with RT- samples or in the absence of template.  Ct values were determined by the SDS 2.4 
software after manually setting the threshold to 0.5.  The denaturation curve showed a single 
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peak, representative of a single PCR product.  The average Ct values from quadruplicate 
repeats were calculated.  These were then averaged with values obtained from 2 independent 
qPCR experiments.  Changes in Pde mRNA levels were measured with the ∆∆Ct method, using 
PSMB2 (proteasome subunit beta type 2) as the housekeeping reference and the Pde1b WT 
striatum sample as calibrator (set at 100%).  
Open-Field Locomotor Activity 
One set of mice was given the following tests: Open-field, TST, and FST with sample 
sizes of 8-25 mice per genotype.  Activity was assessed in 40 x 40 cm automated locomotor 
activity chambers (PAS System, San Diego Instruments, San Diego, CA) as described 
(Hautman et al. 2014).  Mice were placed in test chambers for 1 h, and data were collected 
every 5 min.  The total number of infrared beam interruptions was analyzed.  
Tail Suspension Test 
TST followed the method of Cryan et al. (Cryan et al. 2005a).  The apparatus allowed 
the mouse’s tail to be inserted through a hole in a transparent horizontal acrylic plate mounted 
on four legs.  The tail was pulled snuggly against the underneath surface so that no space 
remained between the base of the tail and the plate.  The test was scored manually in 1 min 
intervals during the 5 min test.  Immobility time and latency to the first immobile event were 
scored.  Immobility was defined as the absence of movement except minor paw or nose 
movements.  
Forced Swim Test 
 Mice were placed in a transparent glass cylindrical vessel 10 cm in diameter (i.d.) and 25 
cm tall filled to a depth of 6 cm with 22 ± 1 ºC water.  Two procedures were used.  The first 
group was given a single 6 min trial with minutes 2-6 scored for immobility.  Later groups were 
tested using the 2 day method (Cryan et al. 2005b; Porsolt et al. 1979).  On day 1, mice were 
placed in the vessel for 15 min.  On day 2, mice were given a second trial for 5 min and scored 
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for immobility, latency to immobility, and active swimming.  Immobility was defined as minimal 
movement sufficient to keep the mouse’s nose above water.  The 2 day procedure was used on 
two sets of mice at two separate institutions to verify the phenotype: Cincinnati Children’s 
Research Foundation (Fig. 2D) and Mount St. Joseph University (Fig. 2E). 
Antidepressant Treatment 
 A different set of mice was used for the antidepressant experiment, and these mice also 
received the FST with sample sizes of 8-14 per group.  Antidepressant effects in WT and Pde1b 
KO mice were assessed using the FST.  Different antidepressants show efficacy with different 
doses and dosing regimens, therefore, we used procedures previously found to be effective.  
We chose one SSRI (fluoxetine) and one non-SSRI (bupropion) for comparison.  Drugs were 
given subcutaneously in a volume of 10 mL/kg.  Fluoxetine (20 mg/kg; Sigma-Aldrich, St. Louis, 
MO) was administered three times at 23.5, 5, and 1 h prior to day-2 of FST as per (Mason et al. 
2009).  Bupropion (20 mg/kg; Toronto Research Chemicals, Toronto, Ontario, Canada) was 
administered 30 min before day-2 of FST as per (Dhir and Kulkarni 2008). 
Experiment 2: Effects of stress on PDE1B protein 
Acute Stress 
 Adult male WT mice were rehoused four times in random combinations to normalize the 
gut microbiota between treatment groups (Stappenbeck and Virgin 2016), and cages were 
randomly assigned to stress or non-stress groups (8 mice/group for corticosterone and 12 
mice/group for Western blots).  Mice had a submandibular blood sample taken 48 h before day-
1 of FST or handling in the no-stress group.  Mice in both groups had blood drawn after day-1 
FST or handling.  FST mice were given day-2 of the FST and both groups sacrificed 24 h later.  
Mice were decapitated, blood collected, and brain collected (brain was cut along the midline and 
the striatum, cerebellum, or whole brain collected) and frozen at –80 ºC.  
Chronic Mild Stress 
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 Adult male WT mice were housed 4/cage for one week prior to the start of the chronic 
mild stress (CMS) exposure.  Each cage was randomly assigned to CMS or no-stress groups 
(12/group).  Mice were weighed every third day.  No-stress mice were handled daily to control 
for being removed from cages.  Submandibular blood samples were taken before the first and 
after the last stressor.  For the next three days all mice were tested in the morning in TST and in 
the afternoon in FST, albeit no differences were detected in the behavior of the stressed and 
non-stressed groups on any day.  Twenty-four hours after the final FST mice were euthanized 
and blood, thymus, spleen, adrenal, and brain were collected.  CMS used two stressors per day 
for 21 days (Table 2) (Castaneda et al. 2011).  Stressors were: Tilted cage (tilted 45° with no 
bedding); restraint: mice placed in 50 mL conical centrifuge tubes with holes for air circulation; 
shaker: mice were restrained in 50 mL tubes attached to a shaker plate and rotated at 200 rpm; 
predator: mice were placed in 50 mL tubes and placed in an F344 male rat’s cage; standing 
water: 500 mL of water in cage; dirty rat cage: mice placed in a soiled rat cage; grid floor: mice 
housed in a cage with a wire floor; hypoxia: mice placed in a hypoxia chamber (Biospherix 
Lacona, NY) and exposed to 8% oxygen and 92% nitrogen; cold: mice were placed in boxes in 
a 4 °C room. 
Corticosterone Assay 
 Collected blood was placed in micro-centrifuge tubes with 2% ethylene diamine tetra 
acetic acid as anticoagulant.  Samples were stored on ice and later spun at 610 RCF for 15 min 
at 4 °C.  Plasma was transferred to clean micro-centrifuge tubes and stored at -80 °C.  Plasma 
samples were assayed using a single lot of Enzo Life Sciences® Corticosterone EIA Kits and 
run in duplicate following the manufacturer’s instructions. 
Western Blot 
Frozen brain tissue was homogenized in radioimmuno-precipitation assay buffer with 
protease inhibitors.  Protein was quantified using the BCATM Protein Assay Kit and diluted to 3 
Page 9 of 38 Psychopharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
 
µg/µL.  Western blots were performed using LI-COR Odyssey® procedures.  Primary antibodies 
from Abcam and their dilutions were: rabbit anti-PDE1B C-terminal (Ab170441 or Ab182565) at 
1:500 or 1:5000 respectively, rabbit anti-PDE10A (Ab177933) at 1:1000, and mouse anti-actin 
(Ab3280) at 1:2000 as a loading control.  Odyssey IRDye 680 and 800 secondary antibodies 
were used at a 1:15,000 dilution.  Relative protein levels are quantified using the LI-COR 
Odyssey® scanner and Image Studio analysis software that reads fluorescent intensity of the 
sample normalized to actin.  
Data Analysis 
Data were analyzed using SAS (v9.3, SAS Institute, Cary, NC), where p ≤ 0.05 was the 
threshold for significance.  To control for litter effects only one mouse per treatment group per 
genotype per litter was used.  T-tests were used when there was only two levels of an 
independent variable, i.e., genotype (KO vs WT) or stress (stress vs no-stress).  In these cases 
dependent variables were immobility time, protein level, or organ weight.  Results from t-tests 
are presented as ordinary means ± standard error of the mean (SEM).  Where there were more 
than two factors, mixed linear model ANOVAs were used.  In these analyses data are presented 
as least square mean ± SEMs.  Two way ANOVAs were used when between subject factors 
were genotype (KO vs WT) and drug (saline, fluoxetine, or bupropion) or genotype (KO vs HET 
vs WT) and sex.  A three way ANOVA was used when the factors were genotype, gene (Pde 
1A, 1B, 1C, 2, 4A, 4B, 4D, 10), and brain region (striatum, cerebellum, or whole brain).  
Repeated measure ANOVA was used for body weight, blood samples, and locomotor activity 
interval.  Mixed models used the autoregressive-1 covariance matrix and Kenward-Roger first 
order adjusted degrees of freedom.  Litter was a random factor in ANOVA models. 
 
Results 
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Experiment 1: KO mice phenotype and mRNA Pde isoform expression 
RT-qPCR 
Expression of mRNA was assessed by RT-qPCR for eight Pde isoforms in the striatum 
and cerebellum (control region) of WT and Pde1b KO mice to confirm complete KO of Pde1b 
and test for compensation by other Pde isoforms.  As shown in Fig. 1A, Pde2 and Pde10a 
expression levels were highest in the striatum, followed by Pde4b and Pde1b.  Expression of all 
Pde isoforms were low in the cerebellum (Fig. 1B) compared with striatum [F(1,112)=2103.7, 
p<0.001].  Pde1b mRNA was abolished in striatum and cerebellum of KO mice [F(1,112)=48.8, 
p<0.001].  Apart from Pde1b, no differences were seen between WT and Pde1b KO mice for 
Pde1a or Pde1c isoforms or for Pde2 or Pde4 mRNA.  There was a significant upregulation of 
Pde10a in KO mice compared with WT mice in the striatum [F(1,112)=58.1, p<0.001], but this 
was not observed in the cerebellum. 
General characteristics and Locomotor Activity 
The appearance and overall behavior of KO mice showed no differences compared with 
WT mice.  No mortality was observed.  KO mice were well groomed and of comparable body 
weight as WT mice.  KO mice were modestly more active in the open-field than WT littermates 
(Fig. 2A; [F(1,21.3)=5.1, p<0.05]) but the effect was not overtly observable. 
Tail Suspension and Forced Swim Tests 
 In order to assess acute stress-depressive related behavior, two tests were used: FST 
and TST.  Fig. 2B shows that Pde1b KO mice had reduced immobility in the TST compared 
with WT mice [t(22)=-4.8, p<0.001].  Similarly, Pde1b KO mice, regardless of FST method, 
showed reduced immobility using a one-day, Fig. 2C [t(14)= 6.3, p<0.001], or two-day 
procedure, Fig. 2D [t(13.8)=-3.1, p<0.01], compared with WT mice.  This was confirmed by 
collaborators in which Pde1b KO mice showed reduced immobility compared with heterozygous 
(p<0.001) and WT littermates (p<0.001), the heterozygous and WT mice did not differ from one 
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another [main effect: F(2,52)=8.2, p<0.001, Fig. 2E].  In addition, no sex differences (p>0.8) 
were found, i.e., Pde1b KO females showed similar reductions in immobility as males.  This 
being the case, only males were used in subsequent experiments.  
Antidepressant treatment in Pde1b KO mice 
 In order to determine if Pde1b deletion is efficacious independent of mechanisms of 
current antidepressants, we tested two drugs from different classes: a selective serotonin 
reuptake inhibitor, fluoxetine, and a norepinephrine-DA reuptake inhibitor, bupropion.  Analysis 
of time spent immobile in the two day FST following treatment with fluoxetine showed significant 
genotype and drug effects [Genotype: F(1,27)=13.1, p<0.01, Drug: F(1,27)=25.0, p<0.001]; the 
interaction was not significant.  KO mice showed a decrease in immobility independent of drug 
compared with WT littermates (Fig. 3A).  Mice given fluoxetine had reduced immobility 
compared with those given saline.  The data suggest that the effects of the KO and fluoxetine 
were additive but not synergistic. 
 A similar effect was seen with bupropion.  There were significant main effects of 
genotype and drug on FST immobility [Genotype: F(1,48)= 20.9, p<0.001, Drug: F(1,48)= 102.2, 
p<0.001] but no interaction.  The KO mice had reduced immobility compared with the WT mice 
regardless of drug treatment: mice treated with bupropion had decreased immobility compared 
with saline treated mice; hence, the effects were additive but not synergistic (Fig. 3B). 
Experiment 2: Effects of acute and chronic stress on PDE1B protein expression 
Acute stress  
 If PDE1B is involved in stress-induced immobility responses, we reasoned that it should 
change in WT mice subjected to acute stress.  Accordingly, we measured corticosterone and 
PDE1B following forced swim stress.  As shown in Fig. 4A, corticosterone levels did not differ 
prior to FST.  After FST, there was the predicted increase in corticosterone [F(2,30.2)=25.2, 
p<0.001] compared with non-stressed controls.  Corticosterone levels returned to baseline 
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levels 48 h following FST.  For PDE1B, there was a stress-induced increase in whole brain 
[F(1,61)=6.3, p<0.05] and in striatum [F(1,61)=4.4, p<0.05] but no change in cerebellum as 
shown in Fig 4B.  There was no change in PDE10A (Fig 4C) in these regions. 
Chronic mild stress 
We next asked, if PDE1B is sensitive to acute stress, would it also be responsive to 
chronic stress?  One common method of inducing chronic stress is CMS.  We therefore tested 
the effect of CMS in WT mice.  No differences in body weight were found prior to CMS, however 
stress decreased body weight after 21 days of CMS [Stress x Day: F(7,139)=11.3, p<0.001] in 
the CMS stressed mice [23.8 ± 0.6 g] compared with non-stressed WT mice [27.2 ± 0.6 g].  As 
expected, CMS-exposed mice had increased corticosterone compared with non-stressed mice 
(p<0.001) after the last stressor, but no differences were noted prior to CMS or after 3 days of 
repeated daily TST and FST testing [CMS X Day: F(2,17.2)=9.5, p<0.01, Fig. 5A].  There was 
also a decrease in thymus weight in relation to body weight in stressed vs. non-stressed mice 
[t(20)=8.0, p<0.001; Thymus: Control=0.128 ± 0.004% Stress=0.060 ± 0.007%] but no change 
in adrenal (Control=0.024 ± 0.003% Stress=0.022 ± 0.002%) or spleen weight (Control=0.316 ± 
0.01% Stress=0.292 ± 0.026%).  PDE1B expression was increased after CMS (Fig 5B) 
whereas PDE10A (Fig 5C) was decreased [PDE1B: t(21)=-3.1, p<0.01, PDE10A: t(19)=2.5, 
p<0.05].  Hence, acute and chronic stress increased PDE1B whereas acute stress had no effect 
on PDE10A and chronic stress decreased PDE10A.  Since PDE1B is not present in Pde1b KO 
mice, there could be no PDE1B changes from stress, therefore, we did not test PDE1B KO mice 
with the CMS procedure. 
 
Discussion 
The phenotype of Pde1b deficient mice on a C57BL6/129svj x C57BL/6N F1 mixed 
hybrid background was reported previously (Reed et al. 2002; Siuciak et al. 2007).  Pde1b KO 
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mice showed several effects, including a probe trial deficit in the Morris water maze (Reed et al. 
2002) and modest hyperactivity in an open-field (Siuciak et al. 2007).  There were no alterations 
in conditioned avoidance learning, elevated zero maze, FST, passive avoidance, hot plate, or 
olfactory orientation (Reed et al. 2002; Siuciak et al. 2007).  However, the breeding strategy 
used in the Siuciak et al. (2007) study was not optimal.  By comparison, we used het x het 
crosses and drew not more than one KO and one WT mouse from any given litter to control 
genetic background and litter effects, whereas Siuciak et al. used KO x KO and WT x WT mice 
from separate lines and did not control for litter.  In order to ensure that our FST results were 
sound, we replicated the finding multiple times using different experiments over a period of 
several years; we also had a collaborator test the mice at another university, and we used the 
TST to confirm our FST phenotype.  The KO immobility effect is not likely to be attributable to 
simple activity differences since we previously showed that KO mice are not different in other 
swimming tests, including the Morris water maze and straight swimming channel.  In these 
tests, KO and WT mice show comparable swim speeds, indicating that KO mice do not differ in 
swimming even if they do show small open-field activity differences (Ehrman et al. 2006; Reed 
2000; Reed et al. 2002).  This is also in agreement with other studies that show that 
spontaneous locomotor activity and swimming are not predictive of one another (Cravens 1974).  
Moreover, by using the two day FST method we reduced the influence of novelty since the mice 
habituate to the forced swim environment on day-1 and immobility is assessed on day-2.  For 
these reasons, we suggest that the present findings are more reliable compared with those of 
Siuciak et al. (2007).  Interestingly though, Siuciak et al. did report increased DA turnover in the 
striatum, which may be involved in the mechanism behind the TST and FST phenotype (Siuciak 
et al. 2007). 
 We show that Pde1b KO mice have complete deletion of DNA and RNA of the catalytic 
region of the Pde1b gene by Southern and Northern blot analyses (Reed et al. 2002).  
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Furthermore, Pde1b KO mice have increased DA, DOPAC, and DA utilization compared with 
WT mice in striatum and hippocampus and reduced 5-HT in striatum and cerebellum (Siuciak et 
al. 2007).  Here we add a comparison by qPCR of expression of mRNA of Pde isoforms in KO 
mice relative to WT mice in striatum and cerebellum.  The relative expression profile in C57BL 
mice is similar to that reported for human and BALB/c mice (Kelly et al. 2014; Lakics et al. 
2010).  However, exceptions exist in human caudate and nucleus accumbens where PDE1B 
expression is the highest isoform expressed, whereas it is higher for Pde2, 4b, and 10a in 
C57BL mice; BALB/c mice show similar expression patterns of Pde1b and 10a (Kelly et al. 
2014; Lakics et al. 2010).  The differences between the expression patterns in different mice 
may be attributable to genetic strain effects, because of primers targeted to different exon 
regions, use of different reference genes, or different methods of normalization.  Regardless of 
these differences, in each case Pde1b and Pde10a are the highest expressing Pde isoforms in 
the striatum and much lower expression in cerebellum that we used as a control region.  As 
expected, Pde1b mRNA was not detected in KO mice.  We found that Pde1b is highly 
expressed in the striatum of WT mice at levels comparable to Pde4b that is known to be 
involved with anxiety and depression (Siuciak et al. 2008; Zhang et al. 2008).  There were no 
differences between WT and Pde1b KO mice in the expression of other Pde1 isoforms (Pde1a 
or 1c).  Thus, no other Pde1 isotype showed compensatory changes in the Pde1b KO mice.  
There were elevated levels of Pde10a in the striatum of KO mice, a region where Pde10a is 
expressed at higher levels than Pde1b.  Interestingly, Schmidt et al. 2010 showed an 
upregulation in striatal Pde1c after administration of the Pde10a inhibitor TP-10 compared with 
controls.  This suggests an inverse relationship between Pde1 and Pde10a (Kleiman et al. 
2011), but our acute vs. chronic stress data suggest that this relationship depends on the 
stimulus and its duration. 
Page 15 of 38 Psychopharmacology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16 
 
To date, the phenotype of Pde10a overexpression has not been investigated in relation 
to depression but Pde10a downregulation has been investigated in relation to schizophrenia.  
Genetic or biochemical inhibition of Pde10a in mouse and rat models, respectively, shows a 
decrease in locomotor activity and in stimulant-induced (PCP, amphetamine, MK-801) 
hyperactivity (Schmidt et al. 2008; Siuciak et al. 2006b).  Other characteristics in Pde10a 
inhibitor-treated or KO rodents include blockade of apomorphine-induced climbing, inhibited 
conditioned avoidance (rats and mice), blockade of NMDA antagonist-induced deficits in 
acoustic startle (rats), improved sensorimotor gating, increased sociability and social odor 
recognition, reversal of stereotypy, and improved novel object recognition (mice) (Grauer et al. 
2009; Höfgen et al. 2010; Schmidt et al. 2008; Siuciak et al. 2006a; Siuciak et al. 2006b).  
Chronic exposure to antipsychotics (haloperidol and clozapine) increases Pde10a (Xu et al. 
2013), suggesting an interaction between Pde10a and the positive symptoms of schizophrenia 
(Dlaboga et al. 2008; Hebb and Robertson 2007; Natesan et al. 2014; Xu et al. 2011).  Siuciak 
et al. 2006a also showed no differences between Pde10a KO and WT mice in the elevated plus 
maze. 
We also tested FST responses after antidepressant treatment to a prototypical selective 
serotonin reuptake inhibitor (fluoxetine) and a prototypical norepinephrine-DA reuptake inhibitor 
(bupropion).  Both WT and KO mice showed reduced immobility from the drugs compared with 
vehicle-treated mice.  Interestingly, the effects of the antidepressants added to the immobility of 
Pde1b KO mice.  The efficacy of the antidepressants independent of the Pde1b deletion 
suggests that the mechanism of immobility induced by the drugs and gene deletion are different.  
This supports the idea that PDE1B may be a useful target for drug development. 
Forced swimming itself increases corticosterone levels, and we used the FST to test for 
changes in PDE1B protein levels in WT mice.  FST caused a significant increase in PDE1B 
protein in striatum and whole brain.  While forced-swim stress causes many changes, the 
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increase in PDE1B is consistent with a role for this enzyme in stress and depression.  CMS was 
used to test chronic stress in WT mice.  After 21 days of CMS, mice showed reduced weight 
gain, elevated plasma corticosterone, and decreased thymus weight all of which are hallmarks 
of stress; they also showed increased PDE1B levels in whole brain, accompanied by decreased 
PDE10A levels.  These data suggest that PDE1B responds to acute and chronic stress while 
PDE10A responds to chronic but not acute stress.  Xu et al. 2013 showed that corticosterone 
exposure increased Pde2 expression in the hippocampus with a peak 24 h later (Xu et al. 
2013).  A similar phenomenon is seen with PDE1B between acute and chronic stress.  In this 
case, the acute stress increases PDE1B expression more significantly than chronic stress, 
perhaps because of the prolonged exposure to heightened corticosterone. 
 Our data and those of Kleiman et al. suggest a relationship between Pde1(b and c) and 
Pde10a in the striatum (Kleiman et al. 2011).  The phenotype of Pde1b KO mice appears 
specific to the reduction of acute stress-induced depressive-like behavior while the phenotype of 
Pde10a KO mice appears to be specific to the reduction of positive symptom-related behaviors 
(Höfgen et al. 2010). 
 We recognize that constitutive KO mice have limitations compared to the use of 
pharmacological inhibitors.  Specifically, constitutive genetic KO models have ablated gene and 
protein from conception and this can result in compensatory changes during development that 
can be difficult to estimate.  Pharmacological inhibitors can cause changes in neuronal activity 
when applied, whereas genetic KO models may not induce any change in neuronal function.  
Although the current data suggest PDE1B to be a potential target for stress resistant 
depressive-like effects, further research is necessary to establish this association.  Spatially and 
temporally targeted reductions of PDE1B is another way to estimate the suitability of this model.  
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Despite the indirect relationship between genetic deletion and a pharmacological treatment, our 
data suggest that changes to Pde1b may open a new avenue for research into depression.  
PDE1 inhibitors have received less consideration for involvement in anxiety and 
depression; however, there are PDE1 inhibitors in clinical trials for other indications (Li et al. 
2016; Snyder et al. 2016).  Given that PDE1B is expressed in high abundance in regions known 
to be involved in anxiety, depression, and other behaviors (Lakics et al. 2010), more research 
on PDE1B is warranted.  
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Tables 
Table 1. Description of mice used in experiments 
Experiment Mice Used Assays Figure 
1 
Males  
WT: n=5 
KO: n=4 
RT-qPCR 1 
1 
Males  
WT: n=12 
KO: n=12 
Locomotor Activity, 
TST, and FST (2 Day) 
2 A,B,D 
1 
Males  
WT: n=8 
WT: n=8 
FST (1 Day) 2 C 
1 
Males & Females 
WT: n=15 
HET: n=25 
KO: n=20 
FST (2 Day) 2 E 
1 
Males  
WT-SAL: n=8 
WT-FLX: n=8 
KO-SAL: n=8 
KO-FLX: n=7 
FST (2 Day)  3 A 
1 
Males  
WT-SAL: n=13 
WT-BUP: n=14 
KO-SAL: n=14 
KO-BUP: n=11 
FST (2 Day) 3 B 
2 
WT Males  
Control: n=8 
Acute Stress: n=8 
Plasma Corticosterone 
and Western Blots 
4 
2 
WT Males  
Control: n=12 
Chronic Stress: n=12 
Plasma Corticosterone 
and Western Blots 
5 
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Table 2. Primer sequences 
Gene Primer Sequence (5’->3’) 
PDE1A GAAGCAAGCGGGGAGCATAG 
AAAGGCAATTAGGCAAGAAACAGG 
PDE1B TTATCAATCTCACCAAGGATG 
GCTGTCTTCATAGTCTTCAC 
PDE1C TTGGTTATTGAGATGGTAATGG 
ATGAGGGATAAGGCTTTCG 
PDE4A CCGTATCCAGGTCCTCAG 
ATGCGATCAGTCCATTGT 
PDE4B CCAGCAGGGAGACAAAGAAC 
ACAATGTAGTCAATGAAACCAACC 
PDE4D GCTTCATAGACTATATCGTTCATC 
GTCCTCCAAAGTGTCCAAG 
PDE2 CACATTGCCATGCCTATCTAC 
CCTTGGTCCAGTGCTCAC 
PDE10A CACTTTGACATTGGTCCTTTCG 
TTCTTCACAGACATGATAAAACGG 
PSMB2 AAATGCGCAATGGATATGAATTG 
GAAGACAGTCAGCCAGGTT 
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Table 3. Chronic Variable Stress Paradigm 
AM (8:00-12:00) PM (13:00-17:00) 
Restraint (2 h) Tilted Cage (24 h) 
Shaker (1 h) Flooded Cage (18 h) 
Predator-Restraint (30 min) Dirty Rat Cage (18 h) 
Cold Room (1 h) Grid Floor (24 h) 
Hypoxia (30 min) Dirty Rat Cage (18 h) 
Restraint (2 h) Flooded Cage (18 h) 
Shaker (1 h) Grid Floor (24 h) 
Hypoxia (30 min) Tilted Cage (24 h) 
No Test 
Restraint (2 h) Tilted Cage (24 h) 
Predator-Restraint (30 min) Dirty Rat Cage (18 h) 
Hypoxia (30 min) Cold Room (1 h) 
Predator-Restraint (30 min) Flooded Cage (18 h) 
Cold Room (1 h) Dirty Rat Cage (18 h) 
Shaker (1 h) Grid Floor (24 h) 
Predator-Restraint (30 min) Hypoxia (30 min) 
No Test 
Restraint (2 h) Flooded Cage (18 h) 
Cold Room (1 h) Grid Floor (24 h) 
Hypoxia (30 min) Tilted Cage (24 h) 
Cold Room (1 h) Shaker (1 h) 
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Figure Captions 
Figure 1 Pde expression in WT and KO mice striatum and cerebellum. Pde1a, Pde1b, 
Pde1c, Pde2, Pde4a, Pde4b, Pde4d, and Pde10a mRNA expression levels were 
measured by RT-qPCR in the striatum (A) and cerebellum (B) in WT and KO 
Pde1b mice.  Percent mRNA expression was normalized to Pde1b WT striatum, 
set at 100%.  Data are represented as LS Mean ± SEM (WT n=5, KO n=4). ***p ≤ 
0.001. 
Figure 2 Pde1b KO produced resistance to induced immobility in FST and TST compared 
with WT littermates.  A, KO mice have increased locomotor activity (WT n=11, KO 
n=12).  B, TST (WT n=12, KO n=12).  C, 1-day 6 min FST method (WT n=8, cKO 
n=8). D, 2 day FST method with 5 min on day 2 (WT n=10, KO n=12). E, 2 day 
FST method with 5 min on day 2 (WT n=15, Het n=25, KO n=20).  KO mice differ 
from both the Het and WT littermates. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
Figure 3 Pde1b KO mice have a similar antidepressant-like phenotype as currently 
marketed antidepressants when compared with WT littermates.  Note that 
antidepressant efficacy occurred independent of the genotype.  A, FST 2-day 
method, day for day-2 (5 min) (WT-Saline n=8 WT-Fluoxetine n=8 KO-Saline n=8 
KO-Fluoxetine n=7).  B, FST 2 day method 5 min (WT-Saline n=13; WT-Bupropion 
n=14; KO-Saline n=14; KO-Bupropion n=11). **p ≤ 0.01, ***p ≤ 0.001.  
Figure 4 PDE1B is elevated by acute stress.  A, Plasma corticosterone was collected 48 h 
prior to stress, right after day-1 FST, and again at sacrifice 24 h later.  B, 
Fluorescent intensity of PDE1B normalized to actin (ab182565, ab3280).  C, 
Fluorescent intensity of PDE10A normalized to actin (ab177933, ab3280).  Tissue 
was collected 24 h after completion of day-2 of the FST.  *p ≤ 0.05, ***p ≤ 0.001 
(Control n=8, Stress n=8). 
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Figure 5 PDE1B is elevated while PDE10A is reduced in chronically stressed mice.  A. 
Plasma for corticosterone was collected 24 h prior to stress, after the 21st day of 
stress, and upon sacrifice.  B, Fluorescent intensity of PDE1B normalized to actin 
(ab170441, ab3280).  C, Fluorescent intensity of PDE10A normalized to actin 
(ab177933, ab3280).  Tissue and blood was collected 24 h after the 3 days of TST 
and FST in both the stressed and control mice. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 
(Control n=12, Stress n=12). 
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Fig. 1 
 
Fig. 2 
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Fig. 3 
 
Fig. 4 
 
Fig. 5 
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